These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9222057)

  • 1. The pharmacokinetics of once-daily oral 400 mg ofloxacin in patients with peritonitis complicating continuous ambulatory peritoneal dialysis.
    McMullin CM; Brown NM; Brown IM; Tomson CR; White LO; Reeves DS; MacGown AP
    J Antimicrob Chemother; 1997 Jun; 39(6):829-31. PubMed ID: 9222057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single- and multiple-dose kinetics of ofloxacin in patients on continuous ambulatory peritoneal dialysis (CAPD).
    Passlick J; Wonner R; Keller E; Essers L; Grabensee B
    Perit Dial Int; 1989; 9(4):267-72. PubMed ID: 2488379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ofloxacin pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
    Chan MK; Chau PY; Chan WW
    Clin Nephrol; 1987 Dec; 28(6):277-80. PubMed ID: 3481692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose pharmacokinetics of intraperitoneal ofloxacin in patients on continuous ambulatory peritoneal dialysis.
    Cheng IK; Chau PY; Kumana CR; Chan CY; Kou M; Siu LK
    Perit Dial Int; 1993; 13 Suppl 2():S383-5. PubMed ID: 8399617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral treatment of peritonitis in CAPD patients with ofloxacin.
    Chan MK; Chau PY; Chan WW
    Nephrol Dial Transplant; 1988; 3(2):194-7. PubMed ID: 3140086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple-dose-kinetics of ofloxacin after intraperitoneal application in CAPD patients.
    Kampf D; Borner K; Hain H; Conrad W
    Perit Dial Int; 1991; 11(4):317-21. PubMed ID: 1751596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ofloxacin in drug-resistant tuberculosis.
    Chulavatnatol S; Chindavijak B; Chierakul N; Klomsawat D
    J Med Assoc Thai; 2003 Aug; 86(8):781-8. PubMed ID: 12948278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral treatment of peritonitis in CAPD patients with two dosage regimens of ofloxacin.
    Chan MK; Chau PY; Chan WW
    J Antimicrob Chemother; 1988 Sep; 22(3):371-5. PubMed ID: 3182430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The case for oral treatment of peritonitis in continuous ambulatory peritoneal dialysis.
    Passadakis P; Oreopoulos D
    Adv Perit Dial; 2001; 17():180-90. PubMed ID: 11510271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAPD peritonitis and fluoroquinolones: a review.
    Janknegt R
    Perit Dial Int; 1991; 11(1):48, 53-8. PubMed ID: 2049423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure.
    White LO; MacGowan AP; Mackay IG; Reeves DS
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():65-72. PubMed ID: 3182464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.
    Mars RL; Moles K; Pope K; Hargrove P
    Adv Perit Dial; 2000; 16():280-4. PubMed ID: 11045311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose pharmacokinetics of ofloxacin during continuous venovenous hemofiltration in critical care patients.
    Fuhrmann V; Schenk P; Mittermayer C; El Menyawi I; Ratheiser K; Thalhammer F
    Am J Kidney Dis; 2003 Aug; 42(2):310-4. PubMed ID: 12900813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is monotherapy with cefazolin or ofloxacin an adequate treatment for peritonitis in CAPD patients?
    Gucek A; Bren AF; Lindic J; Hergouth V; Mlinsek D
    Adv Perit Dial; 1994; 10():144-6. PubMed ID: 7999813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preliminary report on the pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in patients with chronic renal failure.
    White LO; MacGowan AP; Lovering AM; Reeves DS; Mackay IG
    Drugs; 1987; 34 Suppl 1():56-61. PubMed ID: 3481329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics and dose adaptation of ofloxacine, pefloxacine and ciprofloxacine during haemodialysis and continuous ambulatory peritoneal dialysis].
    Daniel JP; Moulin B; Christmann D
    Ann Pharm Fr; 2004 May; 62(3):177-85. PubMed ID: 15243351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gender on the pharmacokinetics of ofloxacin.
    Sowinski KM; Abel SR; Clark WR; Mueller BA
    Pharmacotherapy; 1999 Apr; 19(4):442-6. PubMed ID: 10212016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
    Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
    Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of ofloxacin. An overview.
    Flor S
    Am J Med; 1989 Dec; 87(6C):24S-30S. PubMed ID: 2603892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sodium fusidate and ofloxacin on Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis.
    Sesso R; Parisio K; Dalboni A; Rabelo T; Barbosa D; Cendoroglo M; Pignatari A; Draibe S; Ajzen H
    Clin Nephrol; 1994 Jun; 41(6):370-6. PubMed ID: 8076441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.